Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Why Sonnet BioTherapeutics (SONN) Stock Is Getting Hammered

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) shares are trading lower by 27.6% to $1.31 Wednesday morning after the company announced the pricing of a public offering involving 2,843,750 shares of common stock or pre-funded warrants, along with investor warrants allowing the purchase
byHenry Khederian
October 25, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) shares are trading lower by 27.6% to $1.31 Wednesday morning after the company announced the pricing of a public offering involving 2,843,750 shares of common stock or pre-funded warrants, along with investor warrants allowing the purchase of up to 5,687,500 shares of common stock.

What Else?

Sonnet BioTherapeutics says the combined offering price is $1.60 per share, totaling approximately $4.55 million in gross proceeds before expenses. Each investor warrant is exercisable for one share of common stock at $1.60 per share over five years.

The offering is set to close around October 27, 2023, and is led by existing investors, with Chardan and Ladenburg Thalmann & Co. Inc. serving as joint book-running managers.

Sonnet BioTherapeutics says the funds raised will be utilized for research and development, including clinical trials, as well as general corporate purposes.

See Also: Why Alphatec (ATEC) Stock Is Nosediving

According to data from Benzinga Pro, Sonnet BioTherapeutics has a 52-week high of $65.93 and a 52-week low of $1.10.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Drive-Thru Cannabis Sales Help C21: Same-Store Sales Up, But Revenue Down In Q3

By Jelena Martinovic
December 14, 9:36 AM
C21 Investments reported a 4.5% year-over-year and a 3.9% sequential decrease in revenue to $6.9 million for the third quarter ended October 31. The Vancouver-based company also reported a sequential increase in same-store sales. Gross profit totaled $2.7 million, down from $3.9 million in the prior year's quarter, and the net loss was $376,150 compared to net income of $248,507 in the same period last year. C21 Investments generated $0.9 million of adjusted EBITDA, unchanged from the prior quarter, and cash at the end of Q3 was $1.9 million, unchanged since the start of the year.

CSE:CXXI